Details
Stereochemistry | ACHIRAL |
Molecular Formula | Zn |
Molecular Weight | 65.3956 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[ZnH2+2]
InChI
InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N
InChI=1S/Zn/q+2
Molecular Formula | Zn |
Molecular Weight | 65.3956 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459http://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6309044
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459http://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6309044
Diammonium Zinc Disulfate is commonly used in fluid fertilizers. It is effective if properly applied in the soil (band application) and is less costly than chelate forms of zinc.
CNS Activity
Sources: http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicityhttps://www.ncbi.nlm.nih.gov/pubmed/2307275https://www.ncbi.nlm.nih.gov/pubmed/25374537 | https://www.ncbi.nlm.nih.gov/pubmed/15639165https://www.ncbi.nlm.nih.gov/pubmed/10721938
Curator's Comment:: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.
Originator
Sources: http://www.drugdevelopment-technology.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/http://sciencing.com/uses-zinc-carbonate-7889200.htmlhttps://www.webelements.com/zinc/history.html
Curator's Comment:: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612426 |
|||
Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783 |
|||
Target ID: CHEMBL2364710 |
|||
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194 |
|||
Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
|||
Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | CORTROPHIN-ZINC Approved UseTreatment of ulcerative colitis and other colonic disorders. Launch Date-4.55328006E11 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Secondary | VORAXAZE Approved UseIndicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date1.32675836E12 |
|||
Primary | VUSION Approved UseINDICATIONS AND USAGE
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when
complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or
budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal
culture for Candida albicans is not adequate evidence of candidal infection since colonization
with C. albicans can result in a positive culture. The presence of candidal infection should be
established by microscopic evaluation prior to initiating treatment.
VUSION Ointment should be used as part of a treatment regimen that includes measures
directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and
frequent diaper changes. Launch Date1.140048E12 |
|||
Primary | ZINC OXIDE Approved UseUnknown |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
Primary | ZINC SULFATE Approved UseUnknown Launch Date5.47171205E11 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
In vitro activity of zinc salts against human rhinoviruses. | 1987 Apr |
|
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. | 1991 Sep 10 |
|
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates. | 1993 Aug |
|
New applications for the zinc iodide-osmium tetroxide technique. | 1994 Feb |
|
Iron chelators as therapeutic agents against Pneumocystis carinii. | 1994 May |
|
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha. | 1995 Nov 13 |
|
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. | 1997 Feb |
|
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide. | 1997 May 16 |
|
Thujaplicin-copper chelates inhibit replication of human influenza viruses. | 1998 Aug |
|
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study. | 1999 Spring |
|
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age. | 2004 |
|
Impact of the mother's zinc deficiency on the woman's and newborn's health status. | 2005 |
|
Zinc in attention-deficit/hyperactivity disorder. | 2005 Aug |
|
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. | 2005 Aug |
|
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder. | 2005 Sep 1 |
|
Effects of zinc supplementation in patients with type 1 diabetes. | 2005 Summer |
|
Copper and zinc concentrations in serum of healthy Greek adults. | 2006 Apr 15 |
|
Effect of end-stage renal disease and diabetes on zinc and copper status. | 2006 Jul |
|
Elevated cortical zinc in Alzheimer disease. | 2006 Jul 11 |
|
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality. | 2006 May |
|
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats. | 2006 May |
|
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide. | 2006 Nov 10 |
|
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. | 2007 May |
|
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. | 2007 Nov |
|
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. | 2010 Dec |
|
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. | 2010 Dec |
|
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. | 2010 Dec 1 |
|
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. | 2010 Feb |
|
Glucarpidase following high-dose methotrexate: update on development. | 2010 Jan |
|
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells. | 2010 Jul |
|
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells. | 2011 Jul |
|
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity. | 2011 Jun |
|
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue? | 2011 Mar 1 |
|
Responses of human cells to ZnO nanoparticles: a gene transcription study. | 2011 Nov |
|
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. | 2012 Apr |
|
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface. | 2012 Feb |
|
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung. | 2012 Jun 25 |
|
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4. | 2013 Dec |
|
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation. | 2013 Dec |
|
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. | 2013 Jan |
|
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils. | 2013 Jul 31 |
|
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties. | 2013 Nov 25 |
|
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation. | 2013 Sep |
|
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling. | 2014 Apr |
|
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles. | 2014 Jan |
|
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. | 2014 May 15 |
|
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity. | 2014 May 16 |
|
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand. | 2015 Jan 25 |
|
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. | 2015 Sep |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:26:35 UTC 2021
by
admin
on
Fri Jun 25 21:26:35 UTC 2021
|
Record UNII |
13S1S8SF37
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175530
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
||
|
WHO-ATC |
D09AB01
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
||
|
NCI_THESAURUS |
C68295
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
||
|
NCI_THESAURUS |
C597
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
||
|
DSLD |
137 (Number of products:9660)
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
13S1S8SF37
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | |||
|
DB14532
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | |||
|
N0000175529
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | Decreased Copper Ion Absorption [PE] | ||
|
32051
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | |||
|
1546264
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | RxNorm | ||
|
C68296
Created by
admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
|
PRIMARY | |||
|
23713-49-7
Created by
admin on Fri Jun 25 21:26:35 UTC 2021 , Edited by admin on Fri Jun 25 21:26:35 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
LIGAND->TARGET |
Scientific Literature
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |